Mar 11, 2025 8:45am EDT Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Feb 26, 2025 9:00am EST Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Feb 19, 2025 8:35am EST Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
Feb 18, 2025 9:15am EST Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
Feb 13, 2025 8:30am EST Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
Feb 13, 2025 8:00am EST Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
Jan 28, 2025 9:05am EST Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
Jan 22, 2025 8:35am EST Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Jan 21, 2025 9:05am EST Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
